{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:06:05Z","timestamp":1791911165121,"version":"4.3.4"},"reference-count":49,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Gastroenterol"],"accepted":{"date-parts":[[2016,5,6]]},"published-print":{"date-parts":[[2016,6]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Clinical trials of several new treatments for opioid-induced constipation (OIC), chronic idiopathic constipation (CIC) and constipation-predominant irritable bowel syndrome (IBS-C) have focused on differences between subjects relieved of constipation with placebo and active treatment. Patients and clinicians however, are more interested in the probability these treatments provide actual relief of constipation and its associated symptoms.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We searched the medical literature using MEDLINE and Cochrane central register of controlled trials. Randomised, placebo-controlled trials that examined the use of methylnaltrexone, naloxegol, lubiprostone, prucalopride or linaclotide in adults with OIC, CIC and IBS-C were eligible for inclusion. The primary efficacy measure was relief of constipation. Adverse event data for abdominal symptoms were also analysed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Key results and findings<\/jats:title>\n                  <jats:p>25 publications were included in our analyses. The proportion of constipated individuals with active treatment was significantly lower than the proportion with placebo; however, in 15 of these 20 trials analysed, a majority of patients remained constipated with active treatment. Analyses of adverse event data revealed that the percentage of participants who experienced abdominal pain, diarrhoea and flatulence with active treatment was higher than that with placebo in the majority of trials analysed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Newer pharmacological treatments for constipation are superior to placebo in relieving constipation, but many patients receiving active treatment may remain constipated. In addition, all 5 of the treatments studied are accompanied by no change or a possible increase in the prevalence of abdominal symptoms, such as abdominal pain, diarrhoea and flatulence.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjgast-2016-000094","type":"journal-article","created":{"date-parts":[[2016,6,20]],"date-time":"2016-06-20T11:43:01Z","timestamp":1466422981000},"page":"e000094","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":22,"title":["Persistent constipation and abdominal adverse events with newer treatments for constipation"],"prefix":"10.1136","volume":"3","author":[{"given":"Irene","family":"Sonu","sequence":"first","affiliation":[{"name":"Stanford University School of Medicine, Palo Alto, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Triadafilopoulos","sequence":"additional","affiliation":[{"name":"Stanford University School of Medicine, Palo Alto, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry D","family":"Gardner","sequence":"additional","affiliation":[{"name":"Science for Organizations, Inc., Mill Valley, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2016,6,1]]},"reference":[{"key":"2025073013494203000_3.1.e000094.1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2004.04114.x"},{"key":"2025073013494203000_3.1.e000094.2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01536339"},{"key":"2025073013494203000_3.1.e000094.3","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3111\/13696998.2013.860375","article-title":"Healthcare costs among patients with chronic constipation: a retrospective claims analysis in a commercially insured population","volume":"17","author":"Cai","year":"2014","journal-title":"J Med Econ"},{"key":"2025073013494203000_3.1.e000094.4","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/ajg.2015.64","article-title":"Emergency Department Burden of Constipation in the United States from 2006 to 2011","volume":"110","author":"Sommers","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"2025073013494203000_3.1.e000094.5","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/0016-5085(89)91500-X","article-title":"Psychological and physiological characteristics of patients with severe idiopathic constipation","volume":"97","author":"Wald","year":"1989","journal-title":"Gastroenterology"},{"key":"2025073013494203000_3.1.e000094.6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2007.03376.x"},{"key":"2025073013494203000_3.1.e000094.7","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2015.67"},{"key":"2025073013494203000_3.1.e000094.8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.1999.01642.x"},{"key":"2025073013494203000_3.1.e000094.9","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.11.061"},{"key":"2025073013494203000_3.1.e000094.10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4637.2008.00495.x"},{"key":"2025073013494203000_3.1.e000094.11","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2013.851082"},{"key":"2025073013494203000_3.1.e000094.12","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S61602."},{"key":"2025073013494203000_3.1.e000094.13","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2012.10.029"},{"key":"2025073013494203000_3.1.e000094.14","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.14309\/00000434-200901001-00002","article-title":"An evidence-based systematic review on the management of irritable bowel syndrome","volume":"104","author":"Brandt","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"2025073013494203000_3.1.e000094.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0707377"},{"key":"2025073013494203000_3.1.e000094.16","first-page":"39","article-title":"Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients","volume":"7","author":"Slatkin","year":"2009","journal-title":"J Support Oncol"},{"key":"2025073013494203000_3.1.e000094.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2010.11.008"},{"key":"2025073013494203000_3.1.e000094.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310246"},{"key":"2025073013494203000_3.1.e000094.19","doi-asserted-by":"crossref","unstructured":"Webster L , Chey WD , Tack J , et al . Randomised clinical trial: the long-term safety and tolerability of naloxegol in patients with pain and opioid-induced constipation. Aliment Pharmacol Ther 2014;771\u20139. doi:10.1111\/apt.12899","DOI":"10.1111\/apt.12899"},{"key":"2025073013494203000_3.1.e000094.20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2007.01524.x"},{"key":"2025073013494203000_3.1.e000094.21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2007.03320.x"},{"key":"2025073013494203000_3.1.e000094.22","doi-asserted-by":"publisher","DOI":"10.1111\/pme.12437"},{"key":"2025073013494203000_3.1.e000094.23","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-009-1068-x"},{"key":"2025073013494203000_3.1.e000094.24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2982.2011.01668.x"},{"key":"2025073013494203000_3.1.e000094.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2014.08.026"},{"key":"2025073013494203000_3.1.e000094.26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2008.03629.x"},{"key":"2025073013494203000_3.1.e000094.27","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2008.03881.x"},{"key":"2025073013494203000_3.1.e000094.28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0800670"},{"key":"2025073013494203000_3.1.e000094.29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2008.03884.x"},{"key":"2025073013494203000_3.1.e000094.30","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2008.162404"},{"key":"2025073013494203000_3.1.e000094.31","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2982.2010.01533.x"},{"key":"2025073013494203000_3.1.e000094.32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2982.2012.01983.x"},{"key":"2025073013494203000_3.1.e000094.33","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-010-1229-y"},{"key":"2025073013494203000_3.1.e000094.34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1010863"},{"key":"2025073013494203000_3.1.e000094.35","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2008.59"},{"key":"2025073013494203000_3.1.e000094.36","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.12.050"},{"key":"2025073013494203000_3.1.e000094.37","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.08.041"},{"key":"2025073013494203000_3.1.e000094.38","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2012.254"},{"key":"2025073013494203000_3.1.e000094.39","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2012.255"},{"key":"2025073013494203000_3.1.e000094.40","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/nmo.12292","article-title":"Effect of linaclotide in irritable bowel syndrome with constipation (IBS-C): a systematic review and meta-analysis","volume":"26","author":"Atluri","year":"2014","journal-title":"Neurogastroenterol Motil"},{"key":"2025073013494203000_3.1.e000094.41","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12571"},{"key":"2025073013494203000_3.1.e000094.42","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2013.169"},{"key":"2025073013494203000_3.1.e000094.43","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2010.227132"},{"key":"2025073013494203000_3.1.e000094.44","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2013.04.032"},{"key":"2025073013494203000_3.1.e000094.45","unstructured":"StatMate [Internet]. (cited 7 Sep 2015). http:\/\/www.graphpad.com.laneproxy.stanford.edu\/scientific-software\/statmate\/"},{"key":"2025073013494203000_3.1.e000094.46","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12985"},{"key":"2025073013494203000_3.1.e000094.47","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.00528.2003"},{"key":"2025073013494203000_3.1.e000094.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2010.03.015"},{"key":"2025073013494203000_3.1.e000094.49","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2982.2001.00280.x"}],"container-title":["BMJ Open Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgast-2016-000094","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T20:49:51Z","timestamp":1753908591000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopengastro.bmj.com\/lookup\/doi\/10.1136\/bmjgast-2016-000094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,6,1]]},"published-print":{"date-parts":[[2016,6]]}},"alternative-id":["10.1136\/bmjgast-2016-000094"],"URL":"https:\/\/doi.org\/10.1136\/bmjgast-2016-000094","relation":{},"ISSN":["2054-4774"],"issn-type":[{"value":"2054-4774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6]]}}}